ELCC 2016 | Characterizing tumor-infiltrating lymphocytes in resectable early stage NSCLC
David Carbone
At the 6th European Lung Cancer Conference (ELCC), held in Geneva, Switzerland, from 13–16 April 2016, David Carbone, MD, PhD, from The Ohio State University Wexner Medical Center, Columbus, OH, discusses the characterization of tumor-infiltrating lymphocytes in resectable early stage non-small cell lung cancer (NSCLC) and the application of this understanding for the development of immunotherapy in early stage disease.
Related videos
0:55
TTFields as an anti-mitotic therapy
Ori Farber
0:48
The LUNAR study: TTFields for treating NSCLC
Ori Farber
2:03
The STELLAR study: TTFields for malignant pleural mesothelioma
Ori Farber
1:35
Afatinib for advanced EGFRm-positive NSCLC
Antonio Passaro
2:03
TKIs to treat EGFRm-positive NSCLC
Marina Garassino
